Drug discovery and therapeutic innovation

Here at The Institute of Cancer Research, we are a powerhouse of drug discovery. Since 2005, 13 of our drugs have entered clinical trials, and many more current cancer medicines are rooted in discoveries made here. The key to our success is team science, with ICR researchers working across disciplines to create innovative approaches to cancer therapeutics.

The ICR hosts the world-leading Centre for Cancer Drug Discovery, previously known as Cancer Research UK Cancer Therapeutics Unit, which has discovered 21 new targeted drug candidates since 2005 – more than any other academic centre in the world. Thirteen of these have gone into clinical development.

In addition to this, abiraterone – a drug for prostate cancer discovered at the ICR – is now standard treatment for advanced prostate cancer and has benefited hundreds of thousands of men with the disease worldwide.

We also discovered how to genetically target the drug olaparib, which is now used on the NHS for treating women with ovarian cancer who have BRCA mutations, and has been approved in the US for a similar subset of women with breast cancer.

And our science underpinned the discovery of the drug classes BRAF inhibitors and PI3K inhibitors.

Meeting the challenges of cancer evolution and drug resistance

Over the coming years our focus, laid out in our research strategy, will be on the discovery of drugs designed to meet the challenges of cancer evolution and drug resistance.

We aim to discover greater numbers of exciting new cancer treatments, including a new drug targeted against a novel evolutionary mechanism, and a new immunotherapy.

As part of this, work has already begun to create new drug discovery facilities closely integrated with the work of our Centre for Evolution and Cancer.

Our commercialisation successes

The ICR works with industry to commercialise its discoveries as the fastest way of taking new drugs and technologies to patients, and ploughs income earned back into its research so further patients can benefit.

We are the most successful academic institution in the world at discovering new cancer drugs – discovering 20 new targeted cancer drugs, and taking 11 new drugs into clinical trials, since 2005 alone.

Abiraterone, kinase inhibitors and Hsp90 inhibitors are examples of the ICR's success at drug discovery, and the importance of our partnerships with industry in taking drugs into trials.

In the 2012/13 academic year the ICR received more than £10 million in invention income – an average of more than £19,000 per academic staff member.

Invention income

An analysis using figures from the Higher Education Statistics Agency ranks the ICR first in the UK, followed by the University of Belfast, the University of Cambridge, Aston University and Oxford Brookes University, for size-adjusted income. We also ranked second for absolute levels of invention income, behind only the much larger University of Cambridge.

The ICR’s invention income per $1,000 of research spend would place it in the top 10 of US universities for which figures are publicly available – ranking above some of the world’s leading universities including Stanford and Massachusetts Institute of Technology.